Physician profile
Isha Kothari
NPI 1154629541
$7,284.79
in general payments reported to CMS, 2019-2025
22 companies · $2,581 in 2025
The $2,581 reported for 2025 was more than what 95% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $171 · 2022: $196 · 2023: $1,443 · 2024: $2,894 · 2025: $2,581.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,869 · Education: $48.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,869.30 |
| Education | $48.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,151.71 | 2023-2025 | Spravato |
| Abbvie INC. | $1,038.81 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $835.23 | 2022-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Alkermes, INC. | $762.71 | 2021-2025 | Lybalvi, Aristada |
| Axsome Therapeutics, INC. | $652.24 | 2023-2025 | Auvelity |
| Neurocrine Biosciences, INC. | $621.71 | 2023-2025 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $567.81 | 2022-2025 | Caplyta |
| Supernus Pharmaceuticals, INC. | $399.68 | 2023-2025 | Qelbree, Qelbree |
| Teva Pharmaceuticals USA, INC. | $363.85 | 2023-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Tris Pharma INC | $247.32 | 2023-2025 | Dyanavel Xr |
| Corium, LLC | $204.41 | 2023-2025 | Azstarys |
| Vanda Pharmaceuticals INC. | $134.25 | 2025 | Fanapt |
| Lundbeck LLC | $76.21 | 2023-2025 | Abilify Asimtufii, Rexulti |
| Noven Therapeutics, LLC | $35.08 | 2024 | Xelstrym, Secuado |
| Takeda Pharmaceuticals U.S.A., INC. | $32.79 | 2025 | Trintellix |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $32.15 | 2021-2025 | Sublocade |
| Ironshore Pharmaceuticals INC. | $27.37 | 2024 | |
| Neos Therapeutics, LP | $23.41 | 2024 | Adzenys Xr-Odt |
| Bausch Health US, LLC | $22.70 | 2023 | Aplenzin |
| Tempus Ai, INC | $20.55 | 2024 | |
| Collegium Pharmaceutical, INC. | $20.45 | 2025 | Jornay Pm |
| Biogen, INC. | $14.35 | 2025 | Zurzuvae |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Isha Kothari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.